Perhaps JPS… but not from what I have seen firsthand. Be it that what I have seen has been done through the biggest and most credible. We are talking marketing approval which is based after but around the drug data itself. Which has passed comparably… it is not the massive obstacle you suggest. Results are undeniable and the only knock back in this case will be insufficient data ……. Not likely! And data could be re-accumulated in any event!
This particular drug won’t be pulled after market… you’ll have to reasarch it to learn for yourself!
I’m not here to give advice regarding this it is just IMO.
DYOR,and Good luck!
next announcement and likely content, page-129
-
- There are more pages in this discussion • 28 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
